Patients
RECURRENCE
Eligible patients were 18 years or older, had a previous, histologically verified diagnosis of GB, and presented with a first recurrence documented by magnetic resonance imaging (MRI). Key inclusion criteria were indication for alkylating chemotherapy, Karnofsky performance status score greater than or equal to 60, and willingness to refrain from alcoholic beverages if randomized to the experimental treatment with disulfiram. Radiotherapy within 3 months before diagnosis of progression was a main exclusion criteria to reduce the risk of including patients with so-called pseudoprogression after radiotherapy. Prior chemotherapy for progression or other experimental therapies for GB were not allowed. Additional inclusion and exclusion criteria are listed in 